RSV Vaccine Patent Litigation Filed

GlaxoSmithKline Plc filed a lawsuit alleging Pfizer Inc.'s respiratory syncytial virus (RSV) vaccine infringes on four patents for AREXVY™ RSV OA, a single dose, monovalent RSV vaccine.

AREXVY was the first RSV vaccine approved by the U.S. Food and Drug Administration.

Pfizer's RSV vaccine was the second one approved. 

Bloomberg Law reported on August 2, 2023, the GlaxoSmithKline Biologicals SA et al v. Pfizer Inc. complaint was filed in the U.S., District of Delaware.

"Upon information and belief, Pfizer knowingly uses GSK's claimed inventions in ABRYSVO™, a bivalent prefusion F subunit vaccine, without permission," wrote GSK.

GSK is seeking a jury trial, monetary damages, and is asking a judge to prevent Pfizer from selling Abrysvo to adults 60 and older in the U.S.

The U.S. Centers for Disease Control and Prevention announced on June 29, 2023, and July 21, 2023, the use of RSV vaccines for people ages 60 years and older, requires shared clinical decision-making.